Your browser doesn't support javascript.
loading
Clinic-based diabetes screening at the time of HIV testing and associations with poor clinical outcomes in South Africa: a cohort study.
Kubiak, Rachel W; Kratz, Mario; Motala, Ayesha A; Galagan, Sean; Govere, Sabina; Brown, Elisabeth R; Moosa, Mahomed-Yunus S; Drain, Paul K.
Afiliação
  • Kubiak RW; Department of Epidemiology, Health Sciences Building, University of Washington, Seattle, WA, USA. rwkubiak@uw.edu.
  • Kratz M; Department of Epidemiology, Health Sciences Building, University of Washington, Seattle, WA, USA.
  • Motala AA; Cancer Prevention Program, Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
  • Galagan S; Department of Medicine, University of Washington, Seattle, WA, USA.
  • Govere S; Department of Diabetes and Endocrinology, University of KwaZulu-Natal, Durban, South Africa.
  • Brown ER; Department of Global Health, University of Washington, Seattle, WA, USA.
  • Moosa MS; AIDS Healthcare Foundation, Durban, South Africa.
  • Drain PK; Statistical Center for HIV/AIDS Research and Prevention, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
BMC Infect Dis ; 21(1): 789, 2021 Aug 10.
Article em En | MEDLINE | ID: mdl-34376173
ABSTRACT

BACKGROUND:

HIV clinical care programs in high burden settings are uniquely positioned to facilitate diabetes diagnosis, which is a major challenge. However, in sub-Saharan Africa, data on the burden of diabetes among people living with HIV (PLHIV) and its impact on HIV outcomes is sparse.

METHODS:

We enrolled adults presenting for HIV testing at an outpatient clinic in Durban. Those who tested positive for HIV-infection were screened for diabetes using a point-of-care hemoglobin A1c (HbA1c) test. We used log-binomial, Poisson, and Cox proportional hazard models adjusting for confounders to estimate the relationship of diabetes (HbA1c ≥ 6.5%) with the outcomes of HIV viral suppression (< 50 copies/mL) 4-8 months after antiretroviral therapy initiation, retention in care, hospitalization, tuberculosis, and death over 12 months.

RESULTS:

Among 1369 PLHIV, 0.5% (n = 7) reported a prior diabetes diagnosis, 20.6% (95% CI 18.5-22.8%, n = 282) screened positive for pre-diabetes (HbA1c 5.7-6.4%) and 3.5% (95% CI 2.7-4.6%, n = 48) for diabetes. The number needed to screen to identify one new PLHIV with diabetes was 46.5 persons overall and 36.5 restricting to those with BMI ≥ 25 kg/m2. Compared to PLHIV without diabetes, the risk of study outcomes among those with diabetes was not statistically significant, although the adjusted hazard of death was 1.79 (95% CI 0.41-7.87).

CONCLUSIONS:

Diabetes and pre-diabetes were common among adults testing positive for HIV and associated with death. Clinic-based diabetes screening could be targeted to higher risk groups and may improve HIV treatment outcomes.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Infecções por HIV / Fármacos Anti-HIV / Diabetes Mellitus Tipo de estudo: Diagnostic_studies / Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies / Screening_studies Limite: Adult / Humans País como assunto: Africa Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Infecções por HIV / Fármacos Anti-HIV / Diabetes Mellitus Tipo de estudo: Diagnostic_studies / Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies / Screening_studies Limite: Adult / Humans País como assunto: Africa Idioma: En Ano de publicação: 2021 Tipo de documento: Article